Corneal alterations during combined therapy with cyclodextrin/allopregnanolone and miglustat in a knock-out mouse model of NPC1 disease

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Hovakimyan, Marine ^a   Petersen, Jana ^a   Maass, Fabian ^a   Reichard, Maria ^a   Witt, Martin ^a   Lukas, Jan ^a   Stachs, Oliver ^a   Guthoff, Rudolf ^a   Rolfs, Arndt ^a   Wree, Andreas ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; MIGLUSTAT; 1 DEOXYNOJIRIMYCIN; ANESTHETIC AGENT; CYCLODEXTRIN; DRUG DERIVATIVE; ELTANOLONE; ENZYME INHIBITOR; NPC1 PROTEIN, MOUSE; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; COMBINATION CHEMOTHERAPY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORNEA DISEASE; DENDRITIC CELL; DISEASE COURSE; DRUG RESPONSE; ELECTRON MICROSCOPY; EYE EXAMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KNOCKOUT MOUSE; LIPID ANALYSIS; MASS SPECTROMETRY; MOUSE; NIEMANN PICK DISEASE; NONHUMAN; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; CONFOCAL MICROSCOPY; CORNEA; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; LIQUID CHROMATOGRAPHY; LYSOSOME; METABOLISM; METHODOLOGY; MOUSE MUTANT; MUTATION; PATHOLOGY;

1-DEOXYNOJIRIMYCIN; ANESTHETICS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CORNEA; CYCLODEXTRINS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GENOTYPE; LYSOSOMES; MASS SPECTROMETRY; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; MUTATION; NIEMANN-PICK DISEASE, TYPE C; PREGNANOLONE; PROTEINS;

EID: 82755165076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028418     Document Type: Article

References (42)

1. Hers HG, (1965) Inborn lysosomal diseases. Gastroenterology 48: 625-633.
2. Poupetová H, Ledvinová J, Berná L, Dvoráková L, Kozich V, et al. (2010) The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis 33: 387-396.
3. Vanier MT, Millat G, (2003) Niemann-Pick disease type C. Clin Genet 64: 269-281.
4. Millat G, Marçais C, Rafi MA, Yamamoto T, Morris JA, et al. (1999) Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype. Am J Hum Genet 65: 1321-1329.
5. Liscum L, Klansek JJ, (1998) Niemann-Pick disease type C. Curr Opin Lipidol 9: 131-135.
6. Strauss JF 3rd, Liu P, Christenson LK, Watari H, (2002) Sterols and intracellular vesicular trafficking: lessons from the study of NPC1. Steroids 67: 947-951.
7. Vanier MT, Wenger DA, Comly ME, Rousson R, Brady RO, et al. (1988) Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients. Clin Genet 33: 331-348.
8. Vanier MT, Suzuki K, (1998) Recent advances in elucidating Niemann-Pick C disease. Brain Pathol 8: 163-174.
9. Harzer K, Schlote W, Peiffer J, Benz HU, Anzil AP, (1978) Neurovisceral lipidosis compatible with Niemann-Pick disease type C: morphological and biochemical studies of a late infantile case and enzyme and lipid assays in a prenatal case of the same family. Acta Neuropathol 43: 97-104.
10. Elleder M, Jirasek A, Smid F, Ledvinova J, Besley GT, (1985) Niemann-Pick disease type C: study on the nature of the cerebral storage process. Acta Neuropathol Berl 66: 325-336.
11. Suzuki K, Parker CC, Pentchev PG, Katz D, Ghetti B, et al. (1995) Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol 89: 227-238.
12. Iturriaga C, Pineda M, Fernández-Valero EM, Vanier MT, Coll MJ, (2006) Niemann-Pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci 249: 1-6.
13. Vanier MT, (2010) Niemann-Pick disease type C. Orphanet J Rare Dis 3: 5-16.
14. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, et al. (2004) Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204.
15. Zhang M, Li J, Chakrabarty P, Bu B, Vincent I, (2004) Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am J Pathol 165: 843-853.
16. Zhang M, Hallows JL, Wang X, Bu B, Wang W, et al. (2008) Mitogen-activated protein kinase activity may not be necessary for the neuropathology of Niemann-Pick type C mice. J Neurochem 107: 814-822.
17. Zervas M, Somers KL, Thrall MA, Walkley SU, (2001) Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 11: 1283-1287.
18. Lachmann RH, te Vruchte D, Lloyd-Evans E, Reinkensmeier G, Sillence DJ, et al. (2004) Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis 16: 354-358.
19. Chien YH, Lee NC, Tsai LK, Huang AC, Peng SF, et al. (2007) Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis 30: 826.
20. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE, (2007) Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 6: 765-772.
21. Pineda M, Wraith JE, Mengel E, Sedel F, Hwu WL, et al. (2009) Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab 98: 243-249.
22. Wraith JE, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, et al. (2010) Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 99: 351-357.
23. Griffin LD, Gong W, Verot L, Mellon SH, (2004) Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 10: 704-711.
24. Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, et al. (2006) Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Prot Natl Acad Sci USA 103: 13807-13812.
25. Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, et al. (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 4: e6951.
26. Hovakimyan M, Stachs O, Reichard M, Mascher H, Lukas J, et al. (2011) Morphological alterations of the cornea in the mouse model of niemann-pick disease type c1. Cornea 30: 796-803.
27. Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, et al. (1997) Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 277: 232-235.
28. Nunes A, Pressey SN, Cooper JD, Soriano S, (2011) Loss of amyloid precursor protein in a mouse model of Niemann-Pick type C disease exacerbates its phenotype and disrupts tau homeostasis. Neurobiol Dis 42: 349-359.
29. Morris MD, Bhuvaneswaran C, Shio H, Fowler S, (1982) Lysosome lipid storage disorder in NCTR-BALB/c mice. I. Description of the disease and genetics. Am J Pathol 108: 140-149.
30. Xie C, Turley SD, Dietschy JM, (1999) Cholesterol accumulation in tissues of the Niemann-pick type C mouse is determined by the rate of lipoprotein-cholesterol uptake through the coated-pit pathway in each organ. Proc Natl Acad Sci U S A 96: 11992-11997.
31. Sawamura N, Gong JS, Garver WS, Heidenreich RA, Ninomiya H, (2001) Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem 276: 10314-10319.
32. Claudepierre T, Paques M, Simonutti M, Buard I, Sahel J, et al. (2009) Lack of Niemann-Pick type C1 induces age-related degeneration in the mouse retina. Mol Cell Neurosci 43: 164-176.
33. Abel LA, Walterfang M, Fietz M, Bowman EA, Velakoulis D, (2009) Saccades in adult Niemann-Pick disease type C reflect frontal, brainstem, and biochemical deficits. Neurology 72: 1083-1086.
34. Brady RO, (1978) Ophthalmologic aspects of lipid storage diseases. Ophthalmology 85: 1007-1013.
35. Biswas J, Nandi K, Sridharan S, Ranjan P, (2008) Ocular manifestation of storage diseases. Curr Opin Ophthalmol 19: 507-511.
36. Palmer M, Green WR, Maumenee IH, Valle DL, Singer HS, et al. (1985) Niemann-Pick disease-type C. Ocular histopathologic and electron microscopic studies. Arch Ophthalmol 103: 817-822.
37. Emery JM, Green WR, Huff DS, Sloan HR, (1972) Niemann-Pick disease (type C). Histopathology and ultrastructure. Am J Ophthalmol 74): 1144-1154.
38. Herrmann WA, von Mohrenfels CW, Lohmann CP, (2004) Confocal microscopy and corneal sensitivity in a patient with corneal manifestations of Tangier disease. Cornea 23: 825-827.
39. Falke K, Büttner A, Schittkowski M, Stachs O, Kraak R, et al. (2009) The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal laser-scanning microscopy study. Graefes Arch Clin Exp Ophthalmol 247: 523-534.
40. Tavares R, Coelho D, Macário MC, Torres A, Quadrado MJ, et al. (2009) Evaluation of treatment with cysteamine eyedrops for cystinosis with confocal microscopy. Cornea 28: 938-940.
41. Maegawa GH, van Giersbergen PL, Yang S, Banwell B, Morgan CP, et al. (2009) Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis. Mol Genet Metab 97: 284-291.
42. Tavakoli M, Boulton AJ, Efron N, Malik RA, (2010) Increased Langerhan cell density and corneal nerve damage in diabetic patients: role of immune mechanisms in human diabetic neuropathy. Cont Lens Anterior Eye 34: 7-11.